Company / Operating Cash Flow per Share
Protagonist Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.91
FY2025
5-year range
-$2.33 / $2.83
FY2021-FY2025
Trend
-67.9%
vs FY2024
Sector context
#56 of 212
Health Care
What the data says
At $0.91, Protagonist Therapeutics, Inc.'s operating cash flow per share ranks #56 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-4.61 in FY2016 to $2.83 in FY2024.
Based on SEC 10-K filings.
0.91 in FY2025.
Improved from $-1.24 to $0.91 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#56 of 212 in Health CareTop 26% of 212This company $0.91 Sector average -$14.72
▼
+106.2% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 67.9% year-over-year.
- Ranks #56 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2024.
- Lowest operating cash flow per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.91 | -67.9% |
| FY2024 | $2.83 | +328.7% |
| FY2023 | -$1.24 | +43.9% |
| FY2022 | -$2.20 | +5.3% |
| FY2021 | -$2.33 | -10.5% |
| FY2020 | -$2.11 | -31.4% |
| FY2019 | -$1.60 | +28.2% |
| FY2018 | -$2.23 | -1120.6% |
| FY2017 | $0.22 | +104.7% |
| FY2016 | -$4.61 | +91.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026